As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

To attract and retain workers, employers will focus on competitive salaries and flexible benefits, experts say.

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

The GLP-1s include semaglutide (Ozempic, Wegovy) and the combination of GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound).

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...